|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University Hospital, Geneva |
|---|---|
| Information provided by: | University Hospital, Geneva |
| ClinicalTrials.gov Identifier: | NCT00315068 |
Purpose
Catheter ablation using radiofrequency is a new therapeutic tool to treat atrial fibrillation with a higher success rate than medical therapy (80% versus less than 50% respectively). Because of the length of the intervention and of the risk of complications of the procedure, it would be important to determine success rate before the intervention. The information gained from this study will in all probability improve our estimation of the chances of a successful intervention and may enable us to take necessary therapeutic measures in case of an elevated risk of recurrence.
Multiple studies suggest that the 2 markers in this study could provide information of this nature, however, their utility in the radiofrequency catheter ablation treatment of atrial fibrillation has never been demonstrated.
| Condition |
|---|
|
Atrial Fibrillation |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
| Official Title: | The Value of Amino-Terminal Brain Natriuretic Peptide and C-Reactive Protein Serum Levels for Predicting Recurrence of Atrial Fibrillation and/or Atrial Flutter After Radiofrequency Catheter Ablation |
| Estimated Enrollment: | 180 |
| Study Start Date: | April 2004 |
| Estimated Study Completion Date: | August 2007 |
Catheter ablation of atrial fibrillation is a recent therapeutic tool to treat atrial fibrillation. The success rate of eliminating atrial fibrillation by radiofrequency catheter ablation is 80 %, after one or sometimes two procedures, against 20-50 % with drug treatment.
This intervention may be complicated by : hematoma at the puncture site – 1 % incidence; thromboembolic events < 1 % incidence; cardiac perforation with tamponade < 1 %, pulmonary vein stenosis 2 % incidence.
The aim of this study is to evaluate blood tests of biological products (NT-proBNP and CRP) as markers of prognosis and success after radiofrequency catheter ablation for atrial fibrillation.
Previous studies demonstrated the prognostic value of NT-proBNP and CRP in the recurrence of atrial fibrillation after electrical cardioversion. However the prognostic value of these biomarkers was never demonstrated in the setting of radiofrequency catheter ablation of atrial fibrillation.
This is an observation study including 180 patients with the indication of catheter ablation for atrial fibrillation. Confounding factors of increased NT-proBNP will be assessed with echocardiographic imaging.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Switzerland | |
| Cardiology Division University Hospital | |
| Geneva, Switzerland, 1211 | |
| Principal Investigator: | Pierre-Frederic Keller, MD | Cardiology Division University Hospital |
More Information
| Study ID Numbers: | PRD-03-I-03 |
| Study First Received: | April 13, 2006 |
| Last Updated: | April 19, 2007 |
| ClinicalTrials.gov Identifier: | NCT00315068 |
| Health Authority: | Switzerland: Swissmedic |
|
arrythmia atrial fibrillation proteins |
|
Natriuretic Peptide, Brain Heart Diseases Atrial Fibrillation |
Recurrence Atrial Flutter Arrhythmias, Cardiac |
|
Pathologic Processes Cardiovascular Diseases |
